Inducible T-Cell Co-Stimulator Ligand
"Inducible T-Cell Co-Stimulator Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A B7 antigen that binds specifically to INDUCIBLE T-CELL CO-STIMULATOR PROTEIN on T-CELLS. It provides a costimulatory signal for T-cell proliferation and cytokine secretion.
| Descriptor ID |
D060945
|
| MeSH Number(s) |
D12.776.467.150.500 D12.776.543.095.500 D23.050.301.285.500 D23.529.168.500
|
| Concept/Terms |
Inducible T-Cell Co-Stimulator Ligand- Inducible T-Cell Co-Stimulator Ligand
- Inducible T Cell Co Stimulator Ligand
- CD275 Antigen
- Antigen, CD275
- Antigens, CD275
- CD275 Antigens
- B7-Related Protein-1
- B7H2 Antigen
- Antigen, B7H2
- B7-H2 Antigen
- Antigen, B7-H2
- B7 H2 Antigen
- B7-H2 Ligand
- B7 H2 Ligand
- Ligand, B7-H2
- B7-Like Protein Gl50
- B7 Like Protein Gl50
- Protein Gl50, B7-Like
- B7-Related Protein 1
- B7 Related Protein 1
|
Below are MeSH descriptors whose meaning is more general than "Inducible T-Cell Co-Stimulator Ligand".
Below are MeSH descriptors whose meaning is more specific than "Inducible T-Cell Co-Stimulator Ligand".
This graph shows the total number of publications written about "Inducible T-Cell Co-Stimulator Ligand" by people in this website by year, and whether "Inducible T-Cell Co-Stimulator Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Inducible T-Cell Co-Stimulator Ligand" by people in Profiles.
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
-
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017 02 13; 8:14340.
-
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res. 2016 07 01; 76(13):3684-9.
-
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
-
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res. 2014 Feb; 2(2):167-76.
-
CagA-dependent downregulation of B7-H2 expression on gastric mucosa and inhibition of Th17 responses during Helicobacter pylori infection. J Immunol. 2013 Oct 01; 191(7):3838-46.
-
Noncanonical NF-kappaB regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell development. Proc Natl Acad Sci U S A. 2011 Aug 02; 108(31):12827-32.
-
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011 Aug 15; 71(16):5445-54.
-
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 2010 Dec 01; 70(23):9581-90.
-
Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J. 2010 May 05; 29(9):1600-12.